We are live on ! Find out more

30 hedge funds and large institutions have $2.44M invested in iBio in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

6.43% less ownership

Funds ownership: 26.19%19.75% (-6.4%)

12% less funds holding

Funds holding: 3430 (-4)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

76% less capital invested

Capital invested by funds: $10.4M → $2.44M (-$7.96M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
30
Holders Change
-4
Holders Change %
-11.76%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
7
Increased
7
Reduced
2
Closed
10
Calls
Puts
Net Calls
Net Calls Change

IBIO Hedge Fund Activity: Q2 2025 in Review

30 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2025, worth a combined $2.44M — down 76% from $10.4M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of IBIO and 7 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 7 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $734K. The largest seller was Iridian Asset Management, exiting entirely with an estimated $234K sold.

  • 30 institutional investors held iBio (IBIO) as of Q2 2025, down from 34 in Q1 2025.
  • Funds reported $2.44M of iBio stock for Q2 2025, down 76% quarter-over-quarter.
  • 7 funds opened new iBio positions in Q2 2025 and 10 closed out, a net change of -3 holders.
  • The largest iBio buyer in Q2 2025 was Lynx1 Capital Management, an estimated $734K added.
  • The largest iBio seller in Q2 2025 was Iridian Asset Management, an estimated $234K sold.

Based on aggregated 13F filings for Q2 2025.